Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

Koji Sasaki; Sara S. Strom; Susan O’Brien; Elias Jabbour; Farhad Ravandi; Marina Konopleva; Gautam Borthakur; Naveen Pemmaraju; Naval Daver; Preetesh Jain; Sherry Pierce; Hagop M. Kantarjian; Jörge E. Cortes

doi:10.1016/s2352-3026(15)00048-4

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

Koji Sasaki(Tokyo Medical and Dental University), Sara S. Strom(The University of Texas MD Anderson Cancer Center), Susan O’Brien(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Marina Konopleva(The University of Texas MD Anderson Cancer Center), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), Preetesh Jain(The University of Texas MD Anderson Cancer Center), Sherry Pierce(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(The University of Texas MD Anderson Cancer Center)

The Lancet Haematology

April 20, 2015

10.1016/s2352-3026(15)00048-4

Cited by 312Open Access

Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis